Stoke Therapeutics
STOK

$13.76

9.11%

Market Cap: $724M

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

118% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 22

80% more call options, than puts

Call options by funds: $250K | Put options by funds: $139K

57% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 21

12% more funds holding

Funds holding: 102 [Q1] → 114 (+12) [Q2]

7% more capital invested

Capital invested by funds: $785M [Q1] → $842M (+$57.1M) [Q2]

6.1% less ownership

Funds ownership: 125.73% [Q1] → 119.64% (-6.1%) [Q2]

40% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 3 (-2) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

24%

upside

Avg. target

$24

74%

upside

High target

$35

154%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andrew Fein 44% 1-year accuracy 72 / 162 met price target	154%upside $35	Buy Reiterated	11 Sept 2024
Needham Joseph Stringer 67% 1-year accuracy 83 / 123 met price target	60%upside $22	Buy Reiterated	8 Aug 2024
Wedbush Laura Chico 49% 1-year accuracy 36 / 74 met price target	24%upside $17	Outperform Reiterated	11 Jul 2024
Needham Joseph Stringer 67% 1-year accuracy 83 / 123 met price target	60%upside $22	Buy Reiterated	28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about STOK published over the past 30 days

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced highlights from presentations at the 15th European Epilepsy Congress (EEC) related to the Company's work to develop the first disease-modifying medicine for Dravet syndrome. Zorevunersen (STK-001) data showing substantial and sustained reductions in seizures and meaningful improvements in.

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026.

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic area.

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced it will present data from its Dravet syndrome clinical program at the 15th European Epilepsy Congress (EEC) taking place September 7 – 11, in Rome, Italy. The Company is advancing zorevunersen (STK-001), a proprietary antisense oligonucleotide (ASO), as the first potential medicine to add.

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Date: Tuesday, September 10, 2024 Time: 12:00 p.m. ET 2024 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 11:30 a.m.

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago.

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today reported financial results for the second quarter of 2024 and provided business updates including those related to zorevunersen (STK-001), the Company's proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Drave.

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on July 15, 2024, the company granted stock options to purchase an aggregate of 122,900 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

See News Rankings